Gamma Medica, Inc., a Salem, NH-based developer of solutions for early diagnosis of breast cancer, closed a $16m Series A financing.
The round was led by healthcare investment firm Psilos Group Managers, LLC.
Led by Jim Calandra, President and CEO, Gamma Medica designs, builds and services the LumaGEM® MBI system, a commercially available, FDA-cleared planar, dual head, fully solid-state digital imaging system utilizing cadmium zinc telluride (CZT) technology to detect early-stage cancers that are missed by mammography in women with dense breasts.
The company intends to use the funds to expand commercialization of its LumaGEM® Molecular Breast Imaging (MBI) system and its companion product the LumaGUIDE® MBI-guided biopsy module, as well as to fund additional multi-site post-market clinical studies involving several academic research institutions in the U.S.
FinSMEs
16/07/2013